表紙
市場調查報告書
商品編碼
1082804

寵物的耳朵感染疾病治療的全球市場:2022年∼2029年

Global Companion Animal Ear Infection Treatment Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球寵物的耳朵感染疾病治療的市場調查,彙整市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素的分析,未滿足需求,市場規模的轉變·預測,各種區分·地區/各主要國家的明細,競爭環境,主要企業簡介等資訊。

目錄

第1章 調查手法·調查範圍

第2章 市場定義和概要

第3章 摘要整理

第4章 市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 產業分析

  • 供應鏈分析
  • 價格分析
  • 未滿足需求

第6章 COVID-19分析

  • COVID-19:對市場的影響分析
  • COVID-19風暴中的價格動態
  • 供需頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商的策略性舉措
  • 總論

第7章 市場分析:各疾病類型

  • 外耳炎
  • 中耳炎
  • 內耳炎

第8章 市場分析:各動物類型

  • 其他

第9章 市場分析:各投藥法

  • 口服
  • 局部
  • 耳朵

第10章 市場分析:各醫藥品分類

  • 抗菌劑
    • Amoxicillin-clavulanate
    • Enrofloxacin
    • Clindamycin
    • Cefpodoxime
    • 其他
  • 抗真菌劑
    • Itraconazole
    • 其他
  • 皮質類固醇劑
    • Hydrocortisone
    • Flucinolone
    • Triamcinolone
    • Betamethasone
    • Dexamethasone
    • 其他
  • 其他

第11章 市場分析:各流通管道

  • 醫院藥局
  • 零售藥局
  • 線上藥局
  • 其他

第12章 市場分析:各地區

  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第13章 競爭情形

  • 主要的展開·策略
  • 企業佔有率分析
  • 產品基準
  • 關注的主要企業清單

第14章 企業簡介

  • Vetoquinol S.A
  • Elanco
  • Zoetis, Inc.
  • Merck Animal Health
  • Vedco, Inc.
  • Virbac Corporation
  • Bayer Animal Heath
  • Dechra Pharmaceuticals plc
  • Ceva Sante Animale
  • Penn Veterinary Supply, Inc.

第15章 全球寵物的耳朵感染疾病治療市場:DataM

目錄
Product Code: DMVH5238

Market Overview

The global companion animal ear infection treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

An ear infection, also known as otitis media or otitis externa, is an inflammation of the outer, middle, or inner ear canal. The most common site of otitis in an animal is the outer ear, which can deteriorate and spread to the middle ear. Inflammation in the middle ear canal can spread to the inner ear. Ear infections in animals usually result in reddish ears that are painful to touch and exude a foul-smelling substance. A ruptured eardrum is a common complication of a middle ear infection. More severe cases of otitis can result in a partial hearing, loss of balance, nausea and vomiting, and visual nerve difficulties. When it comes to killing yeast, germs, and mites, topical treatments inserted into the ear canal are often highly effective. To help fight germs, yeast, and mites, oral drugs are used with other therapies.

Market Dynamics

Innovative therapies in the clinical trials for otitis externa are expected to drive market growth.

The LED-Illuminated Gel (LIG) appears to be useful in relieving clinical conditions, regulating inflammation, and controlling microorganisms in dogs with otitis externa. It may aid in minimizing or avoiding antibiotic treatment in cases of otitis due to its similar efficacy to SOC. In addition, the lesser frequency of LIG treatment compared to the standard of care may improve therapeutic compliance. Furthermore, Osurnia is a novel, easy-to-use drug for treating ear infections (otitis). In just two weeks, it provides relief to the dog with two simple treatments. Treatments are performed at a veterinary facility, eliminating the need for unpleasant ear cleaning or home treatment. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Side effects of drugs and lack of care, whereas aggressive pets and lack of professionalism are factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Otitis externa in pets is becoming more common, one of the market's major development factors. The disease has largely affected canine pets, which has fueled industry growth. Due to the rigorous lockdown imposed during COVID-19, veterinary clinic activities were constrained, decreasing veterinarian visits. This has had a significant influence on the worldwide market's overall development. However, since the steady recovery from the COVID-19 epidemic, the market has demonstrated a V-shaped growth trajectory.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Otitis Externa segment is expected to hold the largest market share in companion animal ear infection treatment market

The otitis externa segment is expected to dominate in 2021. Otitis externa is an infection of the ear canal epithelium (lining) and adjacent structures, leading to secondary bacterial colonization. It may be linked to various dermatological conditions such as allergy or immune-mediated skin disease and systemic illnesses. It is usually treated; however, it can become chronic in certain situations, necessitating surgical intervention and, in rare cases, leading to deformity and fatal complications. According to several studies, when pedigreed dogs are divided into two groups based on whether they have pendulous or upright ears, otitis externa is between 13 and 14 percent and 5 percent, respectively.

Moreover, otitis externa is most strongly related to certain breeds within each group (whether ears are hanging or upright) and is most common in Cocker Spaniels, Poodles, and German Shepherd Dogs. It's been believed that a dangling ear or an abundance of hair in the ear canal increases humidity, which could encourage the spread of infection caused by a skin condition or irritant. Therefore, it has increased the demand for the treatment. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global companion animal ear infection treatment market

In 2021, North America accounted for the highest revenue share. The growth in the number of veterinarians and veterinary clinics, the existence of major animal health companies, the introduction of veterinary health information systems have enabled real-time diagnosis in the region and the investment in R&D to develop new products are some of the factors the market is expected to boost in the forecast period. For instance, according to AVMA, there will be around 118,624 veterinarians present in the U.S. in 2020. Moreover, to achieve market share, Zoetis invests in R&D to develop new products. After acquiring Bayer in August 2020, Elanco strengthened its market penetration. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the companion animal ear infection treatment market are Vetoquinol S.A, Elanco, Zoetis, Inc., Merck Animal Health, Vedco, Inc., Virbac Corporation, Bayer Animal Heath, Dechra Pharmaceuticals plc, Ceva Sante Animale and Penn Veterinary Supply, Inc.

Vetoquinol S.A:

Overview:

Vetoquinol SA is based in France that works in the healthcare industry. The company specializes in anti-infectives, anti-pain inflammatories, cardiology, nephrology research, development, manufacture, marketing, and sale of veterinary pharmaceuticals and goods. Vetoquinol serves customers worldwide.

­Product Portfolio:

Clavaseptin: It is a palatable antibiotic tablet used in dogs and cats, an antibiotic containing a combination of amoxicillin and a beta-lactomase inhibitor (which overcomes bacteria which are penicillin resistant). In dogs it is mainly used for dental infections, and in cats for skin infections.

Why Purchase the Report?

Visualize the composition of the companion animal ear infection treatment market segmentation by disease type, animal type, mode of administration, drug class, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in companion animal ear infection treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of companion animal ear infection Treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global companion animal ear infection treatment market report would provide an access to an approx. 45+market data table, 40+figures and 200pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Animal Type
  • 3.3. Market Snippet by Mode of Administration
  • 3.4. Market Snippet by Drug Class
  • 3.5. Market Snippet by Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Innovative therapies in the clinical trials for otitis externa are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects of drugs are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Otitis Externa*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Otitis Media
  • 7.4. Otitis Interna

8. By Animal Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Administration
    • 8.1.2. Market Attractiveness Index, By Mode of Administration Segment
  • 8.2. Dogs*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Cats
  • 8.4. Others

9. By Mode of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Administration
    • 9.1.2. Market Attractiveness Index, By Mode of Administration Segment
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Topical
  • 9.4. Otic

10. By Drug Class

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.1.2. Market Attractiveness Index, By Drug Class Segment
  • 10.2. Anti-bacterial*
    • 10.2.1. Amoxicillin-clavulanate
    • 10.2.2. Enrofloxacin
    • 10.2.3. Clindamycin
    • 10.2.4. Cefpodoxime
    • 10.2.5. Others
    • 10.2.6. Introduction
    • 10.2.7. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Anti-fungal
    • 10.3.1. Itraconazole
    • 10.3.2. Others
  • 10.4. Corticosteroids
    • 10.4.1. Hydrocortisone
    • 10.4.2. Flucinolone
    • 10.4.3. Triamcinolone
    • 10.4.4. Betamethasone
    • 10.4.5. Dexamethasone
    • 10.4.6. Others
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Administration
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Administration
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Administration
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Administration
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Administration
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. Vetoquinol S.A*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Elanco
  • 14.3. Zoetis, Inc.
  • 14.4. Merck Animal Health
  • 14.5. Vedco, Inc.
  • 14.6. Virbac Corporation
  • 14.7. Bayer Animal Heath
  • 14.8. Dechra Pharmaceuticals plc
  • 14.9. Ceva Sante Animale
  • 14.10. Penn Veterinary Supply, Inc.

LIST NOT EXHAUSTIVE

15. Global Companion Animal Ear Infection Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us